Fluticasone 50micrograms/dose / Salmeterol 25micrograms/dose inhaler CFC free
Requires a prescription from a doctor or prescriber
Formulation used in the management of asthma and chronic obstructive pulmonary disease
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
6 branded products available
Part of the Sereflo brand family (generic: Fluticasone + Salmeterol)
MHRA licensed products
View all licensed products for Fluticasone + Salmeterol on the MHRA register
Avenor 25micrograms/dose / 50micrograms/dose inhaler
Combisal 25micrograms/dose / 50micrograms/dose inhaler
Seretide 50 Evohaler
Seretide 50 Evohaler
Seretide 50 Evohaler
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 13 · 1999–2025
Showing the 50 most relevant studies, sorted by most relevant.
Peter M.A. Calverley, Romain Pauwels, Jørgen Vestbo, et al.
The Lancet, 2003
- Fluticasone
- Salmeterol Xinafoate
- Adrenergic beta-Agonists
Shawn D. Aaron, Katherine L. Vandemheen, Dean Fergusson, et al.
PubMed, 2007
- Fluticasone
- Salmeterol Xinafoate
- Tiotropium Bromide
Emiel F.�M. Wouters
Thorax, 2005
- Fluticasone
- Salmeterol Xinafoate
- Administration, Inhalation
Mani S. Kavuru, Julian Melamed, Gary N. Gross, et al.
Journal of Allergy and Clinical Immunology, 2000
- Fluticasone
- Salmeterol Xinafoate
- Administration, Inhalation
Leif Bjermer, Hans Bisgaard, Jean Bousquet, et al.
BMJ, 2003
- Fluticasone
- Salmeterol Xinafoate
- Acetates
Jean Bourbeau, Pota Christodoulopoulos, François Maltais, et al.
Thorax, 2007
- Fluticasone
- Salmeterol Xinafoate
- Administration, Inhalation
Shang N, Liu Y, Jin Y
2024
- Pulmonary Disease, Chronic Obstructive
- Bronchodilator Agents
- Hospitalization
Braido F, Vlachaki I, Nikolaidis GF, et al.
2025
- Asthma
- Glycopyrrolate
- Beclomethasone
Recent literature has shown that triple therapy is more effective than dual therapy for individuals with uncontrolled asthma. However, the comparative efficacy between different triple therapies remains unclear. The objective of this study was to determine the comparative efficacy of extra-fine single-inhaler medium-dose (MD) or high-dose (HD) of beclometasone/formoterol/glycopyrronium bromide (BDP/FOR/GLY) compared to other triple therapies in patients whose asthma remains uncontrolled with MD or HD inhaled corticosteroids and long-acting β2-agonists. A systematic literature review identified randomized control trials on adult patients with uncontrolled asthma. Two separate networks were constructed according to patients' previous inhaled-corticosteroid dosage. Network meta-analyses evaluated severe and moderate-to-severe exacerbations, pre-dose forced expiratory volume, and asthma control questionnaire responses at 52 (± 3) weeks. Among single-inhaler triple therapies, MD BDP/FOR/GLY significantly reduced the risk of severe exacerbations (RR [95% CrI] compared to MD fluticasone/umeclidinium/vilanterol: 0.65 [0.49, 0.89]), while HD BDP/FOR/GLY demonstrated an improved trend in reducing severe and moderate-to-severe exacerbations versus HD indacaterol acetate/glycopyrronium bromide/mometasone, fluticasone/umeclidinium/vilanterol, and salmeterol/fluticasone + tiotropium. HD BDP/FOR/GLY and HD BDP/FOR + tiotropium did not differ significantly. Compared to relevant single-inhaler triple therapies, MD and HD BDP/FOR/GLY are associated with a significant benefit or trend for improvement in terms of reducing the rate of severe and moderate-to-severe exacerbations.
Abstract licence: CC BY-NC-ND
A. Rossi, T. van der Molen, R. Olmo, et al.
European Respiratory Journal, 2014
- Fluticasone-Salmeterol Drug Combination
- Administration, Inhalation
- Albuterol
Zhai C, Wang F, Xu R, et al.
2024
- Pulmonary Disease, Chronic Obstructive
- Benzyl Alcohols
- Chlorobenzenes
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
Wikipedia article
formulation used in the management of asthma and chronic obstructive pulmonary disease
Read on WikipediaATC classifications (Wikidata)
Linked open data from Wikidata (Q581334), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.